Scarica l'app Stockscreener
1.58
4.64%
0.07
Dopo l'orario di chiusura:
1.59
0.01
+0.63%
Precedente Chiudi:
$1.51
Aprire:
$1.49
Volume 24 ore:
162.73K
Relative Volume:
0.05
Capitalizzazione di mercato:
$8.16M
Reddito:
-
Utile/perdita netta:
$-13.13M
Rapporto P/E:
-0.2625
EPS:
-6.0188
Flusso di cassa netto:
$-15.15M
1 W Prestazione:
+10.49%
1M Prestazione:
-38.52%
6M Prestazione:
-81.98%
1 anno Prestazione:
-76.91%
Intervallo 1D:
$1.49
$1.65
Intervallo di 1 settimana:
$1.38
$1.65
Portata 52W:
$0.9661
$19.03
Metavia Inc Stock (MTVA) Company Profile
Nome
Metavia Inc
Settore
Industria
Telefono
(857) 702-9600
Indirizzo
545 CONCORD AVENUE, CAMBRIDGE
Compare MTVA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MTVA
Metavia Inc
|
1.58 | 7.80M | 0 | -13.13M | -15.15M | -6.0188 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Metavia Inc Stock (MTVA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-04 | Ripresa | H.C. Wainwright | Buy |
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
Metavia Inc Borsa (MTVA) Ultime notizie
MetaVia Company Profile & Introduction - Moomoo
If You Invested $1,000 in Neurobo Pharmaceuticals Inc (NRBO) - Stock Titan
MetaVia Announces $4 Million At-The-Market Stock Offering - TipRanks
Form 424B5 MetaVia Inc For: 2 July By Investing.com - Investing.com UK
[8-K] MetaVia Inc. Reports Material Event - Stock Titan
Metavia (NASDAQ: MTVA) ups ATM offering limit to $4.0M - Stock Titan
MetaVia Inc. Financial Disclosures & SEC Filings - TradingView
OTC Markets Hosts Virtual Investor Presentation with HH Kim, CEO and President, and Marshall Woodworth, CFO of MetaVia, with David Bautz, PhD, Senior Analyst at Zacks SCR - scr.zacks.com
IMG, MTVA, USREF, TGL: These four stocks trade ex-reverse split on Friday - MSN
MetaVia (MTVA) Stock Forum and Discussion - Moomoo
Why MetaVia Stock Is Surging On Friday? - MSN
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing - GlobeNewswire Inc.
MetaVia Inc. Actuals & Estimates (NASDAQ:MTVA) - TradingView
MetaVia (MTVA) price target increased by 1,000.00% to 159.88 - MSN
Enterprise value to revenue forward of MetaVia Inc. – NASDAQ:MTVA - TradingView
Enterprise value to EBITDA forward of MetaVia Inc. – NASDAQ:MTVA - TradingView
Price to sales forward of MetaVia Inc. – NASDAQ:MTVA - TradingView
MTVA Q1 2026 Earnings: Miss on EPS as Pre‑Revenue Biotech Focuses on PipelineEstimate Revision Count - dars.gov.et
MTVA: Promising obesity and MASH therapies approach key data and partnership milestones this year - TradingView
MetaVia Inc (MTVA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
METAVIA INC (MTVA) Stock Chart - ChartMill
Daily Brief Health Care: Viyash Scientific, Guangdong True Health Medical Technology Development, Island Pharmaceuticals , MetaVia and more - Smartkarma
Daily Brief United States: Boston Dynamics, SpaceX, Bloom Energy Corp, Life Time Group Holdings, Maison Solutions, CTW Cayman, Invesco S&P 500 Momentum ETF, MetaVia, Viomi Technology Co Ltd and more - Smartkarma
MetaVia Inc (MTVA) Institutional Confidence - TradingKey
MetaVia Inc (MTVA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
MetaVia Inc (MTVA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
MetaVia Inc (MTVA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
MetaVia Inc (MTVA) Valuation: PE, PB & Fair Value Analysis - TradingKey
MTVA: Vanoglipel and DA-1726 Data Presented at ADA 2026 Scientific Sessions - Smartkarma
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum - PR Newswire
MetaVia Inc (MTVA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
MetaVia Inc (MTVA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
MetaVia Inc (MTVA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
MTVA Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues R&D Investment - newsline.com
MTVA Technical Analysis & ETF Price Forecast - Intellectia AI
MTVA: DA-1726 and vanoglipol show strong clinical and combination potential, with solid cash runway - TradingView
MTVA: Combination therapies show significant weight loss and metabolic benefits; trials fully funded - TradingView
MetaVia Inc. (MTVA) Surges Over 9%: Key Levels to Watch After Strong MoveSwing Trade Setups - newsline.com
MTVA Q1 2026 Earnings: EPS Miss Amidst Pre-Revenue Stage; Stock Declines 5%Earnings Surprise Score - newsline.com
MetaVia Shareholders Approve Equity Plan and Reverse Split - The Globe and Mail
H.C. Wainwright Maintains MetaVia(MTVA.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Get insights into the top gainers and losers of Tuesday's pre-market session. - ChartMill
MetaVia (MTVA) director awarded 17,186 RSUs vesting in 2027 - Stock Titan
MetaVia (MTVA) awards 17,186 stock units to board director - Stock Titan
MetaVia (MTVA) director gets 17,186 RSUs vesting in 2027 - Stock Titan
MetaVia (MTVA) director Jason Groves awarded 17,186 RSUs in equity grant - Stock Titan
MetaVia (MTVA) director Andrew Koven receives 17,186 deferred RSU grant - Stock Titan
MetaVia Inc. (MTVA) director receives 17,186-share restricted stock grant - Stock Titan
According to documents submitted to the U.S. Securities and Exchange Commission, shareholders of MetaVia Inc have approved a reverse stock split plan, with the specific ratio to be determined within the range of 1-for-5 to 1-for-22. - Bitget
MetaVia (NASDAQ: MTVA) investors back reverse split and equity plan changes - Stock Titan
MetaVia presents promising obesity and metabolic data at ADA 2026 - grafa.com
Metavia Inc Azioni (MTVA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.17%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):